Jag Singh, MD, PhD, is the Associate Chief of the Cardiology Division and Professor of Medicine at Harvard Medical School. He is the Founding Director of the Resynchronization and Advanced Cardiac Therapeutics Program.
- Centers & Specialties
- Clinical Interests
- Cardiac resynchronization therapy for heart failure
- Catheter ablation of atrial fibrillation
- Implantable cardioverter defibrillators (ICD) and pacemakers
- Drug-induced arrhythmias
- Long QT syndrome
- Cardiac arrhythmia
- Medical Education
- MD, BJ Medical College
- PhD, Oxford University
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Cardiovascular Disease
- Clinical Cardiac Electrophysiology
- Foreign Languages
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
Jag Singh, MD, PhD, is the Associate Chief of the Cardiology Division and the Founding Director of the Resynchronization and Advanced Cardiac Therapeutics Program, at the Massachusetts General Hospital Heart Center. Dr. Singh received his medical degree from BJ Medical College, Pune University, India. He completed his internal medicine residency, cardiology and cardiac electrophysiology fellowships at Mass General. He also earned a doctorate from Oxford University, a master of science in clinical investigation from MIT and a research fellowship at the Framingham Heart Study. He is a Professor of Medicine at Harvard Medical School.
Dr. Singh's research interests are in clinical cardiac electrophysiology, with an emphasis on device therapy for heart failure and catheter ablation of atrial fibrillation. His investigative work has focused on improving patient selection strategies, multimodality imaging, lead implantation techniques and follow-up protocols for patients receiving device therapy. Dr. Singh is the national principal investigator on 5 ongoing multi-center clinical trials and is also a member of steering committees for over 20 single and multicenter research studies. He also directs the coronary venous angiography core laboratory for several multicenter research studies. Dr. Singh is on the editorial board of several medical journals, Deputy Editor of the Journal of American College of Cardiology: Clinical EP and editor-in-chief of the Current Treatment Options in Cardiovascular Medicine. Dr. Singh is an internationally recognized speaker and frequently gives lectures at national and international educational forums. Dr. Singh has over 200 publications inclusive of original research articles, clinical communications, text book chapters, review articles and editorials. He has edited a Textbook on Imaging in Electrophysiology.
- Research Summary
- Risk stratification for sudden cardiac death and worsening heart failure. Dr. Singh has done extensive work with the Framingham Heart Study and the MADIT Study group and published several landmark manuscripts.
- Patient selection and predicting response to cardiac resynchronization therapy. Dr. Singh has developed and built a new multidisciplinary program at Massachusetts General Hospital to care for patients with heart failure and implanted devices. His research work has led to the development of a novel response score to predict clinical outcome in this patient group.
- Coronary venous anatomy and novel ventricular lead implantation strategies. Dr. Singh has used novel rotational venography and imaging techniques to propose and substantiate new coronary venous anatomy classification and redefine the best views for lead implantation. Dr. Singh published on the importance of left ventricular lead position and developed new implantation protocols, some of which are being tested prospectively in clinical studies.
- Image integration strategies and multimodality imaging for cardiac resynchronization therapy. Dr. Singh has done some novel work integrating computed tomography, ultrasound and fluoroscopy to create better clinical strategies to facilitate device implantation.
- Device diagnostics and remote monitoring in heart failure patients. Dr. Singh's recent work has focused on the use of remote monitoring and device diagnostics to prognosticate and manage patients.
- Newer drugs and catheter ablation strategies of atrial fibrillation. Dr. Singh is actively engaged in research examining newer drug therapies for atrial fibrillation. His research interests also examine novel approaches to enhance patient selection, imaging and ablative techniques for treating atrial fibrillation.
Singh JP et al. Abnormal rate adaptation of the QT interval is associated with hypertensive left ventricular hypertrophy. J Am Coll Cardiol 1997;29:778.
Singh JP et al. Heritability of heart rate variability: the Framingham Heart Study. Circulation, 1999;99: 2251.
Singh JP et al. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from MADIT II. J Am Coll Cardiol 2005 46:1712.
Singh JP et al. Coronary venous anatomy: a segmental approach to aid cardiac resynchronisation therapy. J Am Coll Cardiol . 2005;46:68.
Heist EK et al, Singh JP. Usefulness of a Novel Response Score to Predict Hemodynamic and Clinical Outcome from Cardiac Resynchronization Therapy. Am J Cardiol. 2006;97:1732-6.
Singh JP, et al. Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy Heart Rhythm. 2006;3:1285.
Tournoux F et al, Singh JP. Echocardiographic Measures of Acute Hemodynamic Response after Cardiac Resynchronization Therapy Predict Long-term Clinical Outcome. European Heart Journal, 2007;28:1143.
Singh JP. Electrical Therapy for Advanced Heart Failure: Is it Time for a Multidisciplinary Approach or a New Subspecialty? Expert Rev Cardiovasc Ther. 2007;5:811.
Singh JP et al. Patient selection and classification for atrial fibrillation ablation: Thinking beyond duration. 2009;6:1522.
Upadhyay G et al, Singh JP. Cardiac Resynchronization in Patients with Atrial Fibrillation: a Meta-analysis of Prospective Cohort Studies. J Am Coll Cardiol 2008;52:1239.
Experts from the Massachusetts General Hospital Institute for Heart, Vascular and Stroke Care present insights and opinions on methods for treating refractory heart failure, genetically determined arrhythmias and atrial fibrillation in an integrated, multispecialty program.
New research from the CRT Program within the Institute for Heart, Vascular, and Stroke Care at Massachusetts General Hospital shows that providing multidisciplinary integrated CRT care improves patient outcomes.
Anita Levy, 59, arrived at Massachusetts General Hospital in 2012 with severe heart failure. The mother of four, grandmother of eight and wife of 38 years, was starting to lose hope. After trying a number of therapies without success, her doctors informed her she was a candidate for a new clinical trial.
Jagmeet Singh, MD, Director of the Cardiac Resynchronization Therapy Program at the Massachusetts General Hospital Heart Center, discusses his team's recent study about multidisciplinary care (MC) versus conventional care (CC) in CRT (cardiac resynchronization therapy) patients.
February is American Heart Month, and the spotlight is on heart health. Throughout this month, we will be featuring articles including discussions with physicians in the Massachusetts General Heart Center to learn more about the topics surrounding heart disease, the leading cause of death in the U.S. for both men and women.
It's estimated that more than 5 million Americans are affected by heart failure—a condition characterized by the slow, progressive deterioration of the heart's pumping ability. The syndrome occurs when the ventricles become too weak to pump sufficient blood to the body or when the ventricles become stiff, hindering blood from filling the heart. Often, heart failure is accompanied by a buildup of fluid pressure in the pulmonary blood vessels.
MGH Hotline 07.24.09 Doctors at the MGH Heart Center have implanted the first patient with a new device they hope will reduce hospitalizations for heart failure.
A new clinical trial at the Massachusetts General Hospital Heart Center gives patients the power to monitor their hearts and change their medication dosing daily to prevent the symptoms of heart failure.
New wireless technology allows Heart Center clinicians to keep tabs on heart failure patients wherever they are.
In 2008, the Massachusetts General Hospital Transplant Center completed the most heart transplants in the region. Personal trainer and strongman competitor, Jim Murphy, is one shining example of the great successes of the program.
Resynching a Heart -- and a Life: Bob's Story
Jane and Bob Wass have been married for 59 years and rarely leave one another’s side. Jane left Bob at home for 35 minutes one afternoon and, when she returned, she found Bob had collapsed from a heart attack. They went to Mass General, where they learned he had a dyssynchrony. Bob's care team implanted a pacemaker and defibrillator, and he experienced an immediate improvement in his health. The team continues to monitor Bob’s heart remotely.
55 Fruit Street
Boston MA, 02114-2696